Acknowledgements
This work was supported by National Research Foundation of Korea (NRF) funded by the Korean government (MSIT) (No. 2020R1A2C3003784, No.2020M3A9I4038454), the Faculty Research Assistance Program of Yonsei University College of Medicine (6-2020-0184), the Parts/Materials Development Project in 2021 (20016564) funded by the Ministry of Trade, Industry & Energy (MOTIE, Korea), the Brain Korea 21 Project for Medical Science, Yonsei University and by grants from NHLBI (R01HL150877, R01HL156008), American Heart Association Transformational Project Award (20TPA35490282).
Competing Interests
The authors have declared that no competing interest exists.
1. Horvath P, Aulner N, Bickle M, Davies AM, Nery ED, Ebner D. et al. Screening out irrelevant cell-based models of disease. Nat Rev Drug Discov. 2016;15:751-69
2. Hay M, Thomas DW, Craighead JL, Economides C, Rosenthal J. Clinical development success rates for investigational drugs. Nat Biotechnol. 2014;32:40-51
3. Liang P, Lan F, Lee AS, Gong T, Sanchez-Freire V, Wang Y. et al. Drug screening using a library of human induced pluripotent stem cell-derived cardiomyocytes reveals disease-specific patterns of cardiotoxicity. Circulation. 2013;127:1677-91
4. Frommeyer G, Eckardt L. Drug-induced proarrhythmia: risk factors and electrophysiological mechanisms. Nat Rev Cardiol. 2016;13:36-47
5. Kannankeril PJ, Roden DM. Drug-induced long QT and torsade de pointes: recent advances. Curr Opin Cardiol. 2007;22:39-43
6. Tang CPS, McMullen J, Tam C. Cardiac side effects of bruton tyrosine kinase (BTK) inhibitors. Leuk Lymphoma. 2018;59:1554-64
7. Yonemizu S, Masuda K, Kurata Y, Notsu T, Higashi Y, Fukumura K. et al. Inhibitory effects of class I antiarrhythmic agents on Na(+) and Ca(2+) currents of human iPS cell-derived cardiomyocytes. Regen Ther. 2019;10:104-11
8. Burridge PW, Li YF, Matsa E, Wu H, Ong SG, Sharma A. et al. Human induced pluripotent stem cell-derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity. Nat Med. 2016;22:547-56
9. Von Hoff DD, Layard MW, Basa P, Davis HL Jr, Von Hoff AL, Rozencweig M. et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med. 1979;91:710-7
10. Lefrak EA, Pitha J, Rosenheim S, Gottlieb JA. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer. 1973;32:302-14
11. Woosley RL. Cardiac actions of antihistamines. Annu Rev Pharmacol Toxicol. 1996;36:233-52
12. Glassman AH, Bigger JT Jr. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry. 2001;158:1774-82
13. Johnson RA, Palacios I. Dilated cardiomyopathies of the adult (second of two parts). N Engl J Med. 1982;307:1119-26
14. Matsumori A, Matoba Y, Sasayama S. Dilated cardiomyopathy associated with hepatitis C virus infection. Circulation. 1995;92:2519-25
15. Gintant GA, Limberis JT, McDermott JS, Wegner CD, Cox BF. The canine Purkinje fiber: an in vitro model system for acquired long QT syndrome and drug-induced arrhythmogenesis. J Cardiovasc Pharmacol. 2001;37:607-18
16. Kramer J, Obejero-Paz CA, Myatt G, Kuryshev YA, Bruening-Wright A, Verducci JS. et al. MICE models: superior to the HERG model in predicting Torsade de Pointes. Sci Rep. 2013;3:2100
17. Food Drug Administration HHS. International Conference on Harmonisation; guidance on S7B Nonclinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals; availability. Notice. Fed Regist. 2005;70:61133-4
18. Redfern WS, Carlsson L, Davis AS, Lynch WG, MacKenzie I, Palethorpe S. et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res. 2003;58:32-45
19. Pontes Soares C, Midlej V, de Oliveira ME, Benchimol M, Costa ML, Mermelstein C. 2D and 3D-organized cardiac cells shows differences in cellular morphology, adhesion junctions, presence of myofibrils and protein expression. Plos One. 2012;7:e38147
20. Abbott A. Cell culture: biology's new dimension. Nature. 2003;424:870-2
21. Bokhari M, Carnachan RJ, Cameron NR, Przyborski SA. Culture of HepG2 liver cells on three dimensional polystyrene scaffolds enhances cell structure and function during toxicological challenge. J Anat. 2007;211:567-76
22. Li Y, Huang G, Li M, Wang L, Elson EL, Lu TJ. et al. An approach to quantifying 3D responses of cells to extreme strain. Sci Rep. 2016;6:19550
23. Li CL, Tian T, Nan KJ, Zhao N, Guo YH, Cui J. et al. Survival advantages of multicellular spheroids vs. monolayers of HepG2 cells in vitro. Oncol Rep. 2008;20:1465-71
24. Jabs J, Zickgraf FM, Park J, Wagner S, Jiang X, Jechow K. et al. Screening drug effects in patient-derived cancer cells links organoid responses to genome alterations. Mol Syst Biol. 2017;13:955
25. Shadrin IY, Allen BW, Qian Y, Jackman CP, Carlson AL, Juhas ME. et al. Cardiopatch platform enables maturation and scale-up of human pluripotent stem cell-derived engineered heart tissues. Nat Commun. 2017;8:1825
26. Mills RJ, Parker BL, Quaife-Ryan GA, Voges HK, Needham EJ, Bornot A. et al. Drug Screening in Human PSC-Cardiac Organoids Identifies Pro-proliferative Compounds Acting via the Mevalonate Pathway. Cell Stem Cell. 2019;24:895-907 e6
27. Vlachogiannis G, Hedayat S, Vatsiou A, Jamin Y, Fernandez-Mateos J, Khan K. et al. Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. Science. 2018;359:920-6
28. Voges HK, Mills RJ, Elliott DA, Parton RG, Porrello ER, Hudson JE. Development of a human cardiac organoid injury model reveals innate regenerative potential. Development. 2017;144:1118-27
29. Giacomelli E, Bellin M, Sala L, van Meer BJ, Tertoolen LG, Orlova VV. et al. Three-dimensional cardiac microtissues composed of cardiomyocytes and endothelial cells co-differentiated from human pluripotent stem cells. Development. 2017;144:1008-17
30. Uzun AU, Mannhardt I, Breckwoldt K, Horvath A, Johannsen SS, Hansen A. et al. Ca(2+)-Currents in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes Effects of Two Different Culture Conditions. Front Pharmacol. 2016;7:300
31. Mannhardt I, Breckwoldt K, Letuffe-Breniere D, Schaaf S, Schulz H, Neuber C. et al. Human Engineered Heart Tissue: Analysis of Contractile Force. Stem Cell Reports. 2016;7:29-42
32. Goldfracht I, Protze S, Shiti A, Setter N, Gruber A, Shaheen N. et al. Generating ring-shaped engineered heart tissues from ventricular and atrial human pluripotent stem cell-derived cardiomyocytes. Nat Commun. 2020;11:75
33. Giacomelli E, Meraviglia V, Campostrini G, Cochrane A, Cao X, van Helden RWJ. et al. Human-iPSC-Derived Cardiac Stromal Cells Enhance Maturation in 3D Cardiac Microtissues and Reveal Non-cardiomyocyte Contributions to Heart Disease. Cell Stem Cell. 2020;26:862-79 e11
34. Varzideh F, Mahmoudi E, Pahlavan S. Coculture with noncardiac cells promoted maturation of human stem cell-derived cardiomyocyte microtissues. J Cell Biochem. 2019;120:16681-91
35. Yoshida S, Miyagawa S, Fukushima S, Kawamura T, Kashiyama N, Ohashi F. et al. Maturation of Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes by Soluble Factors from Human Mesenchymal Stem Cells. Mol Ther. 2018;26:2681-95
36. Lundy SD, Zhu WZ, Regnier M, Laflamme MA. Structural and functional maturation of cardiomyocytes derived from human pluripotent stem cells. Stem Cells Dev. 2013;22:1991-2002
37. Kamakura T, Makiyama T, Sasaki K, Yoshida Y, Wuriyanghai Y, Chen J. et al. Ultrastructural maturation of human-induced pluripotent stem cell-derived cardiomyocytes in a long-term culture. Circ J. 2013;77:1307-14
38. Ronaldson-Bouchard K, Ma SP, Yeager K, Chen T, Song L, Sirabella D. et al. Advanced maturation of human cardiac tissue grown from pluripotent stem cells. Nature. 2018;556:239-43
39. Tiburcy M, Hudson JE, Balfanz P, Schlick S, Meyer T, Chang Liao ML. et al. Defined Engineered Human Myocardium With Advanced Maturation for Applications in Heart Failure Modeling and Repair. Circulation. 2017;135:1832-47
40. Tulloch NL, Muskheli V, Razumova MV, Korte FS, Regnier M, Hauch KD. et al. Growth of Engineered Human Myocardium With Mechanical Loading and Vascular Coculture. Circulation Research. 2011;109:47-U195
41. Abilez OJ, Tzatzalos E, Yang HX, Zhao MT, Jung GH, Zollner AM. et al. Passive Stretch Induces Structural and Functional Maturation of Engineered Heart Muscle as Predicted by Computational Modeling. Stem Cells. 2018;36:265-77
42. Yang X, Rodriguez ML, Leonard A, Sun L, Fischer KA, Wang Y. et al. Fatty Acids Enhance the Maturation of Cardiomyocytes Derived from Human Pluripotent Stem Cells. Stem Cell Reports. 2019;13:657-68
43. Correia C, Koshkin A, Duarte P, Hu D, Teixeira A, Domian I. et al. Distinct carbon sources affect structural and functional maturation of cardiomyocytes derived from human pluripotent stem cells. Sci Rep. 2017;7:8590
44. Yang X, Rodriguez M, Pabon L, Fischer KA, Reinecke H, Regnier M. et al. Tri-iodo-l-thyronine promotes the maturation of human cardiomyocytes-derived from induced pluripotent stem cells. J Mol Cell Cardiol. 2014;72:296-304
45. Birket MJ, Ribeiro MC, Kosmidis G, Ward D, Leitoguinho AR, van de Pol V. et al. Contractile Defect Caused by Mutation in MYBPC3 Revealed under Conditions Optimized for Human PSC-Cardiomyocyte Function. Cell Rep. 2015;13:733-45
46. Zhao Y, Rafatian N, Feric NT, Cox BJ, Aschar-Sobbi R, Wang EY. et al. A Platform for Generation of Chamber-Specific Cardiac Tissues and Disease Modeling. Cell. 2019;176:913-27 e18
47. Forsythe SD, Devarasetty M, Shupe T, Bishop C, Atala A, Soker S. et al. Environmental Toxin Screening Using Human-Derived 3D Bioengineered Liver and Cardiac Organoids. Front Public Health. 2018 6
48. Lancaster MA, Knoblich JA. Organogenesis in a dish: modeling development and disease using organoid technologies. Science. 2014;345:1247125
49. Huebsch N, Loskill P, Deveshwar N, Spencer CI, Judge LM, Mandegar MA. et al. Miniaturized iPS-Cell-Derived Cardiac Muscles for Physiologically Relevant Drug Response Analyses. Sci Rep. 2016;6:24726
50. Keung W, Chan PKW, Backeris PC, Lee EK, Wong N, Wong AOT. et al. Human Cardiac Ventricular-Like Organoid Chambers and Tissue Strips From Pluripotent Stem Cells as a Two-Tiered Assay for Inotropic Responses. Clin Pharmacol Ther. 2019;106:402-14
51. Schulze ML, Lemoine MD, Fischer AW, Scherschel K, David R, Riecken K. et al. Dissecting hiPSC-CM pacemaker function in a cardiac organoid model. Biomaterials. 2019;206:133-45
52. Lee EK, Tran DD, Keung W, Chan P, Wong G, Chan CW. et al. Machine Learning of Human Pluripotent Stem Cell-Derived Engineered Cardiac Tissue Contractility for Automated Drug Classification. Stem Cell Reports. 2017;9:1560-72
53. Iyer RK, Odedra D, Chiu LL, Vunjak-Novakovic G, Radisic M. Vascular endothelial growth factor secretion by nonmyocytes modulates Connexin-43 levels in cardiac organoids. Tissue Eng Part A. 2012;18:1771-83
54. Nakane T, Masumoto H, Tinney JP, Yuan F, Kowalski WJ, Ye F. et al. Impact of Cell Composition and Geometry on Human Induced Pluripotent Stem Cells-Derived Engineered Cardiac Tissue. Sci Rep. 2017;7:45641
55. Amano Y, Nishiguchi A, Matsusaki M, Iseoka H, Miyagawa S, Sawa Y. et al. Development of vascularized iPSC derived 3D-cardiomyocyte tissues by filtration Layer-by-Layer technique and their application for pharmaceutical assays. Acta Biomater. 2016;33:110-21
56. Lind JU, Busbee TA, Valentine AD, Pasqualini FS, Yuan H, Yadid M. et al. Instrumented cardiac microphysiological devices via multimaterial three-dimensional printing. Nat Mater. 2017;16:303-8
57. Wang G, McCain ML, Yang L, He A, Pasqualini FS, Agarwal A. et al. Modeling the mitochondrial cardiomyopathy of Barth syndrome with induced pluripotent stem cell and heart-on-chip technologies. Nat Med. 2014;20:616-23
58. Zhang YS, Aleman J, Shin SR, Kilic T, Kim D, Mousavi Shaegh SA. et al. Multisensor-integrated organs-on-chips platform for automated and continual in situ monitoring of organoid behaviors. Proc Natl Acad Sci U S A. 2017;114:E2293-E302
59. Mathur A, Loskill P, Shao K, Huebsch N, Hong S, Marcus SG. et al. Human iPSC-based cardiac microphysiological system for drug screening applications. Sci Rep. 2015;5:8883
60. Forsythe SD, Devarasetty M, Shupe T, Bishop C, Atala A, Soker S. et al. Environmental Toxin Screening Using Human-Derived 3D Bioengineered Liver and Cardiac Organoids. Front Public Health. 2018;6:103
61. Arai K, Murata D, Verissimo AR, Mukae Y, Itoh M, Nakamura A. et al. Fabrication of scaffold-free tubular cardiac constructs using a Bio-3D printer. PLoS One. 2018;13:e0209162
62. Richards DJ, Li Y, Kerr CM, Yao J, Beeson GC, Coyle RC. et al. Human cardiac organoids for the modelling of myocardial infarction and drug cardiotoxicity. Nat Biomed Eng. 2020;4:446-62
63. Archer CR, Sargeant R, Basak J, Pilling J, Barnes JR, Pointon A. Characterization and Validation of a Human 3D Cardiac Microtissue for the Assessment of Changes in Cardiac Pathology. Sci Rep. 2018;8:10160
64. Richards DJ, Coyle RC, Tan Y, Jia J, Wong K, Toomer K. et al. Inspiration from heart development: Biomimetic development of functional human cardiac organoids. Biomaterials. 2017;142:112-23
65. Devarasetty M, Forsythe S, Shupe TD, Soker S, Bishop CE, Atala A. et al. Optical Tracking and Digital Quantification of Beating Behavior in Bioengineered Human Cardiac Organoids. Biosensors (Basel). 2017 7
66. MacQueen LA, Sheehy SP, Chantre CO, Zimmerman JF, Pasqualini FS, Liu X. et al. A tissue-engineered scale model of the heart ventricle. Nat Biomed Eng. 2018;2:930-41
67. Li RA, Keung W, Cashman TJ, Backeris PC, Johnson BV, Bardot ES. et al. Bioengineering an electro-mechanically functional miniature ventricular heart chamber from human pluripotent stem cells. Biomaterials. 2018;163:116-27
68. Tsuruyama S, Matsuura K, Sakaguchi K, Shimizu T. Pulsatile tubular cardiac tissues fabricated by wrapping human iPS cells-derived cardiomyocyte sheets. Regen Ther. 2019;11:297-305
69. Robertson C, Tran DD, George SC. Concise review: maturation phases of human pluripotent stem cell-derived cardiomyocytes. Stem Cells. 2013;31:829-37
70. Yang X, Pabon L, Murry CE. Engineering adolescence: maturation of human pluripotent stem cell-derived cardiomyocytes. Circ Res. 2014;114:511-23
71. Itzhaki I, Rapoport S, Huber I, Mizrahi I, Zwi-Dantsis L, Arbel G. et al. Calcium Handling in Human Induced Pluripotent Stem Cell Derived Cardiomyocytes. Plos One. 2011 6
72. Shimizu T, Yamato M, Isoi Y, Akutsu T, Setomaru T, Abe K. et al. Fabrication of pulsatile cardiac tissue grafts using a novel 3-dimensional cell sheet manipulation technique and temperature-responsive cell culture surfaces. Circ Res. 2002;90:e40
73. Sekine H, Shimizu T, Sakaguchi K, Dobashi I, Wada M, Yamato M. et al. In vitro fabrication of functional three-dimensional tissues with perfusable blood vessels. Nat Commun. 2013;4:1399
74. Zuppinger C. 3D Cardiac Cell Culture: A Critical Review of Current Technologies and Applications. Front Cardiovasc Med. 2019;6:87
75. Burnham MP, Harvey R, Sargeant R, Fertig N, Haddrick M. A Scalable Approach Reveals Functional Responses of iPSC Cardiomyocyte 3D Spheroids. SLAS Discov. 2021;26:352-63
76. Bartosh TJ, Ylostalo JH, Mohammadipoor A, Bazhanov N, Coble K, Claypool K. et al. Aggregation of human mesenchymal stromal cells (MSCs) into 3D spheroids enhances their antiinflammatory properties. Proc Natl Acad Sci U S A. 2010;107:13724-9
77. Lee P, Klos M, Bollensdorff C, Hou L, Ewart P, Kamp TJ. et al. Simultaneous voltage and calcium mapping of genetically purified human induced pluripotent stem cell-derived cardiac myocyte monolayers. Circ Res. 2012;110:1556-63
78. Vunjak-Novakovic G, Bhatia S, Chen C, Hirschi K. HeLiVa platform: integrated heart-liver-vascular systems for drug testing in human health and disease. Stem Cell Res Ther. 2013;4(Suppl 1):S8
79. van Meer BJ, de Vries H, Firth KSA, van Weerd J, Tertoolen LGJ, Karperien HBJ. et al. Small molecule absorption by PDMS in the context of drug response bioassays. Biochem Biophys Res Commun. 2017;482:323-8
80. Shirure VS, George SC. Design considerations to minimize the impact of drug absorption in polymer-based organ-on-a-chip platforms. Lab Chip. 2017;17:681-90
81. Walker DM, Boey G, McDonald LA. The pathology of oral cancer. Pathology. 2003;35:376-83
82. Loessner D, Stok KS, Lutolf MP, Hutmacher DW, Clements JA, Rizzi SC. Bioengineered 3D platform to explore cell-ECM interactions and drug resistance of epithelial ovarian cancer cells. Biomaterials. 2010;31:8494-506
83. Uchida Y, Tanaka S, Aihara A, Adikrisna R, Yoshitake K, Matsumura S. et al. Analogy between sphere forming ability and stemness of human hepatoma cells. Oncol Rep. 2010;24:1147-51
84. Lemme M, Ulmer BM, Lemoine MD, Zech ATL, Flenner F, Ravens U. et al. Atrial-like Engineered Heart Tissue: An In vitro Model of the Human Atrium. Stem Cell Reports. 2018;11:1378-90
85. Drawnel FM, Boccardo S, Prummer M, Delobel F, Graff A, Weber M. et al. Disease modeling and phenotypic drug screening for diabetic cardiomyopathy using human induced pluripotent stem cells. Cell Rep. 2014;9:810-21
86. McKeithan WL, Savchenko A, Yu MS, Cerignoli F, Bruyneel AAN, Price JH. et al. An Automated Platform for Assessment of Congenital and Drug-Induced Arrhythmia with hiPSC-Derived Cardiomyocytes. Front Physiol. 2017;8:766
87. Sharma A, Burridge PW, McKeithan WL, Serrano R, Shukla P, Sayed N. et al. High-throughput screening of tyrosine kinase inhibitor cardiotoxicity with human induced pluripotent stem cells. Sci Transl Med. 2017 9
88. Fairclough RJ, Wood MJ, Davies KE. Therapy for Duchenne muscular dystrophy: renewed optimism from genetic approaches. Nat Rev Genet. 2013;14:373-8
89. Long C, Li H, Tiburcy M, Rodriguez-Caycedo C, Kyrychenko V, Zhou H. et al. Correction of diverse muscular dystrophy mutations in human engineered heart muscle by single-site genome editing. Sci Adv. 2018;4:eaap9004
90. Arad M, Seidman JG, Seidman CE. Phenotypic diversity in hypertrophic cardiomyopathy. Hum Mol Genet. 2002;11:2499-506
91. Cashman TJ, Josowitz R, Johnson BV, Gelb BD, Costa KD. Human Engineered Cardiac Tissues Created Using Induced Pluripotent Stem Cells Reveal Functional Characteristics of BRAF-Mediated Hypertrophic Cardiomyopathy. Plos One. 2016;11:e0146697
92. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S. et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949-54
93. Dhomen N, Marais R. New insight into BRAF mutations in cancer. Curr Opin Genet Dev. 2007;17:31-9
94. Ovchinnikova E, Hoes M, Ustyantsev K, Bomer N, de Jong TV, van der Mei H. et al. Modeling Human Cardiac Hypertrophy in Stem Cell-Derived Cardiomyocytes. Stem Cell Reports. 2018;10:794-807
95. Gollob MH, Green MS, Tang AS, Gollob T, Karibe A, Ali Hassan AS. et al. Identification of a gene responsible for familial Wolff-Parkinson-White syndrome. N Engl J Med. 2001;344:1823-31
96. Hinson JT, Chopra A, Lowe A, Sheng CC, Gupta RM, Kuppusamy R. et al. Integrative Analysis of PRKAG2 Cardiomyopathy iPS and Microtissue Models Identifies AMPK as a Regulator of Metabolism, Survival, and Fibrosis. Cell Rep. 2016;17:3292-304
97. Shinnawi R, Shaheen N, Huber I, Shiti A, Arbel G, Gepstein A. et al. Modeling Reentry in the Short QT Syndrome With Human-Induced Pluripotent Stem Cell-Derived Cardiac Cell Sheets. J Am Coll Cardiol. 2019;73:2310-24
98. Haubner BJ, Schneider J, Schweigmann U, Schuetz T, Dichtl W, Velik-Salchner C. et al. Functional Recovery of a Human Neonatal Heart After Severe Myocardial Infarction. Circ Res. 2016;118:216-21
99. Stevens KR, Kreutziger KL, Dupras SK, Korte FS, Regnier M, Muskheli V. et al. Physiological function and transplantation of scaffold-free and vascularized human cardiac muscle tissue. Proc Natl Acad Sci U S A. 2009;106:16568-73
100. Thavandiran N, Dubois N, Mikryukov A, Masse S, Beca B, Simmons CA. et al. Design and formulation of functional pluripotent stem cell-derived cardiac microtissues. Proc Natl Acad Sci U S A. 2013;110:E4698-707
101. Lemme M, Braren I, Prondzynski M, Aksehirlioglu B, Ulmer BM, Schulze ML. et al. Chronic intermittent tachypacing by an optogenetic approach induces arrhythmia vulnerability in human engineered heart tissue. Cardiovasc Res. 2020;116:1487-99
102. Schaaf S, Shibamiya A, Mewe M, Eder A, Stohr A, Hirt MN. et al. Human Engineered Heart Tissue as a Versatile Tool in Basic Research and Preclinical Toxicology. Plos One. 2011 6
103. Mannhardt I, Saleem U, Mosqueira D, Loos MF, Ulmer BM, Lemoine MD. et al. Comparison of 10 Control hPSC Lines for Drug Screening in an Engineered Heart Tissue Format. Stem Cell Reports. 2020;15:983-98
104. Lesman A, Habib M, Caspi O, Gepstein A, Arbel G, Levenberg S. et al. Transplantation of a tissue-engineered human vascularized cardiac muscle. Tissue Eng Part A. 2010;16:115-25
105. Gao L, Gregorich ZR, Zhu W, Mattapally S, Oduk Y, Lou X. et al. Large Cardiac Muscle Patches Engineered From Human Induced-Pluripotent Stem Cell-Derived Cardiac Cells Improve Recovery From Myocardial Infarction in Swine. Circulation. 2018;137:1712-30
106. Jayawardena TM, Egemnazarov B, Finch EA, Zhang L, Payne JA, Pandya K. et al. MicroRNA-mediated in vitro and in vivo direct reprogramming of cardiac fibroblasts to cardiomyocytes. Circ Res. 2012;110:1465-73
107. Khait L, Birla RK. Cell-based cardiac pumps and tissue-engineered ventricles. Regen Med. 2007;2:391-406
108. Sakalem ME, De Sibio MT, da Costa FAD, de Oliveira M. Historical evolution of spheroids and organoids, and possibilities of use in life sciences and medicine. Biotechnol J. 2021 16
109. Gunti S, Hoke ATK, Vu KP, London NR Jr. Organoid and Spheroid Tumor Models: Techniques and Applications. Cancers (Basel). 2021 13
110. Sato T, Vries RG, Snippert HJ, van de Wetering M, Barker N, Stange DE. et al. Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. Nature. 2009;459:262-U147
111. Lancaster MA, Renner M, Martin CA, Wenzel D, Bicknell LS, Hurles ME. et al. Cerebral organoids model human brain development and microcephaly. Nature. 2013;501:373 -+
112. Fatehullah A, Tan SH, Barker N. Organoids as an in vitro model of human development and disease. Nat Cell Biol. 2016;18:246-54
113. Tuveson D, Clevers H. Cancer modeling meets human organoid technology. Science. 2019;364:952-5
114. Lancaster MA, Huch M. Disease modelling in human organoids. Dis Model Mech. 2019 12
115. Eiraku M, Watanabe K, Matsuo-Takasaki M, Kawada M, Yonemura S, Matsumura M. et al. Self-organized formation of polarized cortical tissues from ESCs and its active manipulation by extrinsic signals. Cell Stem Cell. 2008;3:519-32
116. Lancaster MA, Renner M, Martin CA, Wenzel D, Bicknell LS, Hurles ME. et al. Cerebral organoids model human brain development and microcephaly. Nature. 2013;501:373-9
117. Eiraku M, Takata N, Ishibashi H, Kawada M, Sakakura E, Okuda S. et al. Self-organizing optic-cup morphogenesis in three-dimensional culture. Nature. 2011;472:51-6
118. Nakano T, Ando S, Takata N, Kawada M, Muguruma K, Sekiguchi K. et al. Self-formation of optic cups and storable stratified neural retina from human ESCs. Cell Stem Cell. 2012;10:771-85
119. Spence JR, Mayhew CN, Rankin SA, Kuhar MF, Vallance JE, Tolle K. et al. Directed differentiation of human pluripotent stem cells into intestinal tissue in vitro. Nature. 2011;470:105-9
120. Taguchi A, Kaku Y, Ohmori T, Sharmin S, Ogawa M, Sasaki H. et al. Redefining the in vivo origin of metanephric nephron progenitors enables generation of complex kidney structures from pluripotent stem cells. Cell Stem Cell. 2014;14:53-67
121. Xia Y, Nivet E, Sancho-Martinez I, Gallegos T, Suzuki K, Okamura D. et al. Directed differentiation of human pluripotent cells to ureteric bud kidney progenitor-like cells. Nat Cell Biol. 2013;15:1507-15
122. Takasato M, Er PX, Becroft M, Vanslambrouck JM, Stanley EG, Elefanty AG. et al. Directing human embryonic stem cell differentiation towards a renal lineage generates a self-organizing kidney. Nat Cell Biol. 2014;16:118-26
123. Huch M, Dorrell C, Boj SF, van Es JH, Li VS, van de Wetering M. et al. In vitro expansion of single Lgr5+ liver stem cells induced by Wnt-driven regeneration. Nature. 2013;494:247-50
124. D. A. Fischman AAM. Cardiac Hypertrophy, N. K. Alpert, Ed.. Academic Press, New York. 1971: pp. 125-39.
125. Halbert SP, Bruderer R, Lin TM. In vitro organization of dissociated rat cardiac cells into beating three-dimensional structures. J Exp Med. 1971;133:677-95
126. Hofbauer P, Jahnel SM, Papai N, Giesshammer M, Deyett A, Schmidt C. et al. Cardioids reveal self-organizing principles of human cardiogenesis. Cell. 2021;184:3299-317 e22
127. Schutgens F, Clevers H. Human Organoids: Tools for Understanding Biology and Treating Diseases. Annu Rev Pathol. 2020;15:211-34
128. Drakhlis L, Biswanath S, Farr CM, Lupanow V, Teske J, Ritzenhoff K. et al. Human heart-forming organoids recapitulate early heart and foregut development. Nat Biotechnol. 2021;39:737-46
129. Lewis-Israeli YR, Wasserman AH, Gabalski MA, Volmert BD, Ming Y, Ball KA. et al. Self-assembling human heart organoids for the modeling of cardiac development and congenital heart disease. Nat Commun. 2021;12:5142
130. Song MH, Choi SC, Noh JM, Joo HJ, Park CY, Cha JJ. et al. LEFTY-PITX2 signaling pathway is critical for generation of mature and ventricular cardiac organoids in human pluripotent stem cell-derived cardiac mesoderm cells. Biomaterials. 2021;278:121133
131. Silva AC, Matthys OB, Joy DA, Kauss MA, Natarajan V, Lai MH. et al. Co-emergence of cardiac and gut tissues promotes cardiomyocyte maturation within human iPSC-derived organoids. Cell Stem Cell. 2021;28:2137-52 e6
132. Murry CE, Reinecke H, Pabon LM. Regeneration gaps: observations on stem cells and cardiac repair. J Am Coll Cardiol. 2006;47:1777-85
133. Ye L, Chang YH, Xiong Q, Zhang P, Zhang L, Somasundaram P. et al. Cardiac repair in a porcine model of acute myocardial infarction with human induced pluripotent stem cell-derived cardiovascular cells. Cell Stem Cell. 2014;15:750-61
134. Lind JU, Busbee TA, Valentine AD, Pasqualini FS, Yuan HY, Yadid M. et al. Instrumented cardiac microphysiological devices via multimaterial three-dimensional printing. Nature Materials. 2017;16:303 -+
1. Department of Medicine, Division of Cardiology, Emory University School of Medicine, Atlanta, GA 30322, USA.
2. Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Republic of Korea.
3. Division of Cardiology, Department of Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea.
4. Brain Korea 21 PLUS Project for Medical Science, Yonsei University College of Medicine, Seoul, South Korea.
5. Karis Bio Inc., Seoul, Republic of Korea
* Equal contributions
© 2022. This work is published under https://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.